How Comfrey Works
The active fraction of comfrey is concentrated in the root, which is dug in spring or autumn, dried, and extracted into ointments or creams. The plant produces a distinctive mix of compounds that work on three different layers of musculoskeletal injury — pain signaling, swelling, and the actual repair of damaged connective tissue [4].
Allantoin drives cell proliferation
Comfrey root is unusually rich in allantoin, a small molecule that stimulates fibroblast division and accelerates the closure of small wounds. Allantoin is the same compound that makes mother's milk and slug mucus useful for skin healing, and it is the reason comfrey was historically packed onto cuts, abrasions, and slow-healing ulcers [4]. In ointment form it diffuses through the skin into superficial tissue, where it appears to speed the early proliferative phase of repair.
Rosmarinic acid and choline calm inflammation
Comfrey root contains rosmarinic acid (the same anti-inflammatory polyphenol that makes rosemary and lemon balm useful) along with phenolic acids, mucilage, and choline. Together these inhibit the prostaglandin and leukotriene cascade that drives swelling and bruise pain after a soft-tissue injury [4]. In the ankle-sprain trial against diclofenac, the comfrey arm matched a standard NSAID gel on pain and swelling reduction at every measurement point through day 7 [1] — a striking result, given that diclofenac gel is the topical anti-inflammatory most commonly recommended by sports physicians.
The mucilage acts as a soothing carrier
The leaves and roots are slimy when crushed because they are rich in mucilage — long-chain polysaccharides that form a soothing film on irritated tissue. In a topical preparation this contributes to the cooling, comforting feel that patients consistently rate higher than placebo creams in blinded trials.
How to Use It
The clinical evidence is for standardized topical preparations only — typically Kytta-Salbe (Germany) or Traumaplant (Czech Republic), both of which use comfrey root extract concentrated to a specific allantoin and rosmarinic acid content. Generic comfrey poultices made from garden plants are unlikely to match these in either potency or consistency.
For ankle sprains and acute soft-tissue injury: apply roughly 2 g (a 4 cm strip from the tube) three times daily for up to 8 days, beginning within hours of the injury. In the head-to-head trial against diclofenac gel, this regimen achieved comparable pain relief and faster recovery of range of motion [1][7].
For acute low back pain: the standard regimen in the largest trial was a 4 g application three times daily for 5 days, applied to the lumbar area and rubbed in. Pain on movement fell by 95% in the comfrey arm versus 38% on placebo by day 5 [3].
For knee osteoarthritis: apply twice daily to the affected joint for at least 3 weeks. The 2007 placebo-controlled trial showed clinically meaningful improvements in pain and function, with effect sizes comparable to topical NSAIDs [2].
For best absorption, apply to clean, dry skin and allow it to soak in for several minutes before covering with clothing. Do not apply to broken skin, weeping wounds, or under occlusive bandages — the European Medicines Agency monograph explicitly restricts use to intact skin to minimize absorption of pyrrolizidine alkaloids [8].
See our arnica and boswellia pages for other plant-based topical and oral options for musculoskeletal pain.
The Pyrrolizidine Alkaloid Problem
Comfrey contains a class of compounds called pyrrolizidine alkaloids (PAs) — most notably symphytine, echimidine, and intermedine — that are converted by the liver into reactive metabolites which damage liver cells. In high oral doses they cause hepatic veno-occlusive disease, a serious and sometimes fatal blocking of the small veins of the liver. Long-term oral comfrey has caused human deaths and is genotoxic and carcinogenic in rats [6].
For these reasons, the U.S. FDA in 2001 and most European regulators since have banned oral comfrey products entirely. The European Medicines Agency monograph allows topical use only, restricts treatment duration to no more than 4–6 weeks per year, and excludes use during pregnancy, breastfeeding, and in children under 12 [8]. Modern standardized topical extracts are also produced from PA-depleted comfrey cultivars or processed to remove the alkaloids, so absorption from intact skin is below the level considered toxicologically relevant [4][8].
The bottom line: never take comfrey by mouth, never apply it to broken skin, and stick to commercial PA-depleted ointments rather than homemade preparations from garden plants.
Evidence Review
The clinical case for topical comfrey rests on a small but unusually consistent set of randomized trials, most of them sponsored by the German manufacturer Merck Selbstmedikation, conducted by independent academic centers, and published in mainstream journals.
Predel et al. 2005 (Phytomedicine) is the landmark active-comparator trial: 164 patients with acute unilateral ankle sprain were randomized to either Kytta-Salbe comfrey root ointment or 1% diclofenac gel for one week, with the assessor blinded to treatment. The primary endpoint, pain on tenderness measured by tonometer, fell from 80 mm to 11 mm in the comfrey arm versus 80 mm to 21 mm in the diclofenac arm — a statistically significant superiority for comfrey at p < 0.001 — and the comfrey group recovered ankle joint mobility approximately 1 day faster. Both groups showed similar safety profiles with mild local reactions only. This is rare and important: a herbal extract beating an established NSAID gel in an active-controlled head-to-head trial. [1]
Grube et al. 2007 (Phytomedicine) is the placebo-controlled knee osteoarthritis trial: 220 patients with primary OA of the knee (Kellgren-Lawrence grade II–III) were randomized to comfrey root ointment or matched placebo, applied three times daily for three weeks. The WOMAC pain subscale fell from a baseline of 79.6 mm to 27.9 mm in the comfrey group versus 79.7 mm to 53.4 mm on placebo (p < 0.001), with WOMAC stiffness and function both improving by similar margins and 80% of patients in the active arm rating overall efficacy as good or very good. The effect size of about 1.0 standard deviation is comparable to topical NSAIDs in similar trial designs. [2]
Giannetti et al. 2010 (British Journal of Sports Medicine) tested topical comfrey for acute low back pain in 120 adults randomized to comfrey root extract ointment or placebo, applied three times daily for 5 days. The primary endpoint, pain on standardized active movement scored on a 100-mm visual analog scale, fell by 95.2% in the comfrey arm versus 37.8% on placebo — an enormous effect size. Pain at rest, pressure tenderness, and the Oswestry disability index also separated significantly in favor of comfrey. By day 5, 32% of comfrey patients were pain-free versus 1% of placebo patients. [3]
Kucera et al. 2004 (Wiener Medizinische Wochenschrift) tested an earlier comfrey herb (rather than root) preparation, Traumaplant, in 142 patients with ankle distortion. Comfrey treatment reduced pain on weight-bearing, mobility restriction, and tenderness significantly more than the much weaker comparator (diluted Traumaplant), with a similar adverse event profile. [7]
Smith and Jacobson 2011 (Journal of Chiropractic Medicine) studied a multi-ingredient cream blending comfrey extract with tannic acid in patients with knee OA. While methodologically weaker than the Grube trial because of the multi-ingredient formulation, it confirmed perceived discomfort reduction and quality-of-life improvements over the trial period. [5]
Staiger 2012 (Phytotherapy Research) is the comprehensive clinical overview that synthesized eight prior trials of comfrey ointments across ankle distortion, blunt trauma, back pain, periarthritis, and osteoarthritis, concluding that topical comfrey root extract is effective and well-tolerated for these indications, with adverse events limited to local skin reactions in roughly 2–3% of patients. [4]
Mei et al. 2010 (Journal of Toxicology and Environmental Health, Part B) is the definitive toxicology review documenting the metabolic activation of pyrrolizidine alkaloids — particularly the conversion of symphytine to dehydrosymphytine by hepatic CYP enzymes — and the resulting DNA adduct formation, hepatotoxicity, genotoxicity, and tumorigenicity in oral rodent studies. This is the mechanistic basis for the consistent regulatory restriction of comfrey to topical use only and the exclusion of internal preparations. [6]
The EMA HMPC monograph [8] is the regulatory consensus document: topical use of standardized comfrey root extract is recognized as a "traditional herbal medicinal product" for relief of pain and inflammation in cases of bruises, sprains, and muscle and joint ache. It limits internal exposure to pyrrolizidine alkaloids to less than 0.35 µg per day from a topical preparation on intact skin, restricts continuous use to 4–6 weeks, and prohibits use in pregnancy, lactation, and children.
Strength of evidence: moderate to strong for topical comfrey root extract for acute soft-tissue injury and back pain, with two adequately powered placebo-controlled trials and one active-comparator head-to-head against diclofenac gel. Moderate for knee osteoarthritis pain. The trials share a single sponsor (Merck) but use independent investigators, blinded assessment, and validated endpoints. The principal limitations are the relatively short follow-up (5–21 days) and the absence of long-term safety surveillance for chronic topical use, which the EMA monograph addresses by capping cumulative exposure. Internal use of comfrey is not safe at any dose and should be avoided entirely.